EVUSHELD (tixagevimab and cilgavimab for injection) – Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants

January 17th, 2023
©2023 Newfoundland & Labrador Pharmacy Board